Science and Research

Early IFN-α signatures and persistent dysfunction are distinguishing features of NK cells in severe COVID-19

Longitudinal analyses of the innate immune system, including the earliest time points, are essential to understand the immunopathogenesis and clinical course of coronavirus disease (COVID-19). Here, we performed a detailed characterization of natural killer (NK) cells in 205 patients (403 samples; days 2 to 41 after symptom onset) from four independent cohorts using single-cell transcriptomics and proteomics together with functional studies. We found elevated interferon (IFN)-α plasma levels in early severe COVD-19 alongside increased NK cell expression of IFN-stimulated genes (ISGs) and genes involved in IFN-α signaling, while upregulation of tumor necrosis factor (TNF)-induced genes was observed in moderate diseases. NK cells exert anti-SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) activity but are functionally impaired in severe COVID-19. Further, NK cell dysfunction may be relevant for the development of fibrotic lung disease in severe COVID-19, as NK cells exhibited impaired anti-fibrotic activity. Our study indicates preferential IFN-α and TNF responses in severe and moderate COVID-19, respectively, and associates a prolonged IFN-α-induced NK cell response with poorer disease outcome.

  • Krämer, B.
  • Knoll, R.
  • Bonaguro, L.
  • ToVinh, M.
  • Raabe, J.
  • Astaburuaga-García, R.
  • Schulte-Schrepping, J.
  • Kaiser, K. M.
  • Rieke, G. J.
  • Bischoff, J.
  • Monin, M. B.
  • Hoffmeister, C.
  • Schlabe, S.
  • De Domenico, E.
  • Reusch, N.
  • Händler, K.
  • Reynolds, G.
  • Blüthgen, N.
  • Hack, G.
  • Finnemann, C.
  • Nischalke, H. D.
  • Strassburg, C. P.
  • Stephenson, E.
  • Su, Y.
  • Gardner, L.
  • Yuan, D.
  • Chen, D.
  • Goldman, J.
  • Rosenstiel, P.
  • Schmidt, S. V.
  • Latz, E.
  • Hrusovsky, K.
  • Ball, A. J.
  • Johnson, J. M.
  • Koenig, P. A.
  • Schmidt, F. I.
  • Haniffa, M.
  • Heath, J. R.
  • Kümmerer, B. M.
  • Keitel, V.
  • Jensen, B.
  • Stubbemann, P.
  • Kurth, F.
  • Sander, L. E.
  • Sawitzki, B.
  • Aschenbrenner, A. C.
  • Schultze, J. L.
  • Nattermann, J.

Keywords

  • Covid-19
  • NK cells
  • Tnf
  • antiviral
  • lung fibrosis
  • moderate
  • proteomics
  • scRNA-seq
  • severe
  • type 1 IFN
  • Dioscure Therapeutics SE. F.I.S. is a consultant and shareholder of IFM
  • Therapeutics. J.R.H. is founder and board member of Isoplexis and PACT Pharma.
  • J.D.G. declares contracted research with Gilead, Lilly, and Regeneron. K.H., J.M.J.,
  • and A.J.B. work at Quanterix Corporation. All other authors declare no competing
  • interests.
Publication details
DOI: 10.1016/j.immuni.2021.09.002
Journal: Immunity
Work Type: Original
Location: Assoziierter Partner
Disease Area: PALI
Partner / Member: BIH
Access-Number: 34592166

DZL Engagements

chevron-down